Deutsche Bank AG Makes New $2.37 Million Investment in Immunome, Inc. $IMNM

Deutsche Bank AG bought a new position in shares of Immunome, Inc. (NASDAQ:IMNM) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 111,593 shares of the company’s stock, valued at approximately $2,365,000.

Other large investors have also recently made changes to their positions in the company. Creative Planning grew its holdings in shares of Immunome by 4.0% in the third quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after purchasing an additional 710 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Immunome by 14.4% in the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after buying an additional 935 shares during the period. California State Teachers Retirement System lifted its holdings in Immunome by 1.8% during the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after buying an additional 1,167 shares in the last quarter. Assetmark Inc. lifted its holdings in Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after buying an additional 1,442 shares in the last quarter. Finally, Virtus Investment Advisers LLC lifted its holdings in Immunome by 16.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after buying an additional 1,970 shares in the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Stock Up 0.4%

Shares of NASDAQ:IMNM opened at $28.87 on Friday. The firm has a 50 day moving average of $24.02 and a 200 day moving average of $22.41. The company has a market capitalization of $3.28 billion, a price-to-earnings ratio of -11.41 and a beta of 2.08. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $30.06.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). On average, sell-side analysts expect that Immunome, Inc. will post -2.38 EPS for the current year.

Insider Buying and Selling

In other Immunome news, Director Isaac Barchas sold 11,048 shares of Immunome stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total value of $301,058.00. Following the transaction, the director owned 92,211 shares in the company, valued at $2,512,749.75. The trade was a 10.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the completion of the transaction, the insider owned 50,366 shares of the company’s stock, valued at $1,263,682.94. This represents a 64.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 682,310 shares of company stock worth $15,675,566 in the last three months. 7.21% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on IMNM. HC Wainwright restated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Wall Street Zen lowered shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Leerink Partners decreased their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Barclays initiated coverage on Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. Finally, Wedbush raised their price objective on Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.64.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.